The Class IIa CE certification enables the company to offer best-in-class level technology to physician partners and their patients, solidifying its place in the global market, said Crown Aesthetics president Joe Proctor.
Crown Aesthetics has reported that the British Standards Institution (BSI) today awarded a Class IIa CE certification mark to SkinPen Precision. The certification confirms SkinPen as a treatment to improve the appearance of facial acne scars in adults aged 22 years or older and to improve the appearance of fine lines and wrinkles on the face and neck. The SkinPen is also intended to treat pigmentation conditions (dyschromia) including melasma, vitiligo and solar lentigines.
“This new and expanded certification further validates SkinPen’s safety and usage claims in the EU,” said Joe Proctor, president of Crown Aesthetics. “With SkinPen’s advanced microneedling technology, we continue to set a higher standard in patient care, and firmly establishes the industry benchmark for safety. This essential certification allows us to continue offering best in class technology to our physician partners and their patients and solidifies the company’s growing presence in the global market.”
Since its inception, Crown Aesthetics has committed to safety and innovation, said the company in a press release, ensuring its robust clinical trial program scientifically validates new product indications. And according to the company, when Crown Aesthetics developed the first FDA-cleared SkinPen Precision microneedling device, its trials continue to go beyond required safety measures, setting a new standard for patented device features and technology.
Crown Aesthetics’ non-invasive innovations also include the platelet-rich plasma systems ProGen PRP Advantage and the post-microneedling protocol SKINFUSE, which act as “gateway” products that draw new consumers and revenue to aesthetic practices.
